February 2024 Price Concessions 2nd Update


Following discussions between Community Pharmacy England and the Department of Health and Social Care (DHSC) regarding medicine pricing issues reported by pharmacy owners, the Department has today (16/02/2024) announced the following list of price concessions for February 2024.

Drug Pack size Price concession
Amiloride 5mg tablets 28 £15.59
Amoxicillin 250mg/5ml oral suspension 100 £2.49
Betahistine 16mg tablets 84 £8.50
Betahistine 8mg tablets 84 £4.30
Betamethasone valerate 0.1% cream 100 £5.39
Calcipotriol 0.005% / Betamethasone dipropionate 0.05% ointment 30 £12.12
Clotrimazole 500mg pessaries 1 £9.56
Co-codamol 15mg/500mg tablets 100 £3.28
Dexamfetamine 5mg tablets 28 £22.75
Digoxin 62.5microgram tablets 28 £2.78
Docusate 50mg/5ml oral solution sugar free 300 £17.08
Dorzolamide 20mg/ml / Timolol 5mg/ml eye drops 0.2ml unit dose preservative free 60 £25.03
Duloxetine 30mg gastro-resistant capsules 28 £2.90
Duloxetine 40mg gastro-resistant capsules 56 £11.25
Escitalopram 10mg tablets 28 £1.27
Estradiol 10microgram pessaries 24 £10.75
Ezetimibe 10mg tablets 28 £14.65
Haloperidol 5mg tablets 28 £3.95
Lamotrigine 50mg tablets 56 £2.79
Morphine sulfate 10mg/5ml oral solution 300 £5.45
Orlistat 120mg capsules 84 £23.45
Oxycodone 5mg/5ml oral solution sugar free 250 £9.71
Pregabalin 150mg capsules 56 £2.12
Pregabalin 225mg capsules 56 £2.35
Rasagiline 1mg tablets 28 £47.98
Risperidone 2mg tablets 60 £1.99
Ropinirole 500microgram tablets 28 £15.75
Simvastatin 20mg tablets 28 £1.10
Sulpiride 200mg tablets 30 £3.20
Terbinafine 1% cream 15 £3.54
Terbinafine 1% cream 30 £6.55
Trazodone 150mg tablets 28 £2.18
Zolmitriptan 2.5mg tablets 6 £16.45
Zolmitriptan 2.5mg tablets 12 £32.90
Zopiclone 3.75mg tablets 28 £1.55
Zopiclone 7.5mg tablets 28 £1.56

Please note: We are still in discussion with DHSC on a number other medicines affected by pricing issues this month. We will issue further updates as soon as we hear back from the Department.

No additional endorsements are required for price concessions. A price concession only applies for the month it is granted; any prices agreed for concessions requested late in the month will roll over into the following month.

We encourage pharmacies to report any problems obtaining a Part VIII product at or below the stated Drug Tariff price, using the online feedback form on the Community Pharmacy England website. Please include full details of the supplier and price paid for any products sourced above the Drug Tariff price. We will investigate the extent of the problem and, if appropriate, discuss the issue with DHSC.

Please  subscribe to our mailing list to receive email updates of any price concessions.

Further information on price  concessions and FAQs about the process  involved  can be found on our website (cpe.org.uk/priceconcessions) To hear more on how the current price  concessions system operates, pharmacy teams can now access a recording of our recent Medicines Supply and Concessions Briefing webinar  here.

Improvements to the price concession system

Following significant concerns raised by pharmacies about the unsustainable level of prices imposed by  DHSC  in second half of 2022, it was agreed that an  urgent review of the price concession setting system would take place.

Since this announcement, we have sent a strong and clear message back to Government that pharmacies cannot continue to subsidise the NHS medicines bill. Following the review of the concessionary price process, a package of measures has been developed to improve the system.

One of the solutions agreed between us and DHSC is that from 1st April 2023, all products granted a concessionary price will be classified as ‘Discount Not Deducted’ for the month(s) in which they are on concession.

Furthermore, from May 2023, DHSC has implemented a process to roll over prices to the following month for any concessions requested after the 23rd of the month provided these prices were agreed with us. We are also continuing to work with DHSC on how a ‘retrospective increased payment’ may apply, where appropriate. Further information regarding this concession ‘top-up’ mechanism will be issued once details are finalised.